Comparative clinical and molecular outcomes of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A comprehensive Bayesian network meta-analysis. Hazard ratios ...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...
Association of polypharmacy with acute care utilization in older adults receiving androgen receptor signaling inhibitors for metastatic prostate cancer. Understanding communication and healthcare ...
(CNN) — Harvey Weinstein has been diagnosed with bone cancer, a source close to the incarcerated producer tells CNN. Weinstein’s specific diagnosis is chronic myeloid leukemia, a form of cancer of the ...
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.
The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
Novartis (NVS) announced that Scemblix was granted accelerated approval by the U.S. Food and Drug Administration for adult patients with newly diagnosed Philadelphia chromosome-positive chronic ...
Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...
Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results